Non-endocrine-treated patients with ER+ and pIGF1R/InsRpos tumors had a borderline significant decreased risk of any event after adjustment for prognostic factors and tumor storage time, HRadj (0.39; 95% CI 0.15-1.04). This evidence concerns the gene ESR1 and neoplasm.